WEDNESDAY, Sept. 12, 2018 -- Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the... (Source: Drugs.com - Pharma News)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



Read full article on medworm.com